Class B GPCRs typically bind their peptide ligands through a mechanism known as the two-domain model, in which ECD binds to the C-terminal helix of GLP-1, and the transmembrane domain (TMD) binds to the N-terminal region of GLP-1 (3, 4, 5)
Regulation of intracellular glutathione[J]
And the researchers who published it aren't writing editorials saying "maybe worry about this someday" - they're calling for DXA baselines, resistance training, and protein optimization to become standard of care from day one of GLP-1 therapy
Biochem Biophys Res Commun 320:416423 Yamada R, Taniguchi N, Tanaka T, Ogino C, Fukuda H, Kondo A (2010) Cocktail -integration: a novel method to construct cellulolytic enzyme expression ratio-optimized
Liraglutide was the first GLP-1 receptor analogue approved for the management of obesity, thus starting the new era of gastrointestinal peptide agonist pharmacotherapy for the treatment of both diabetes and obesity
For instance: Wegovy reduces the risk of major cardiovascular events by 20% and is approved for treating metabolic dysfunction-associated steatohepatitis (MASH) with liver scarring